Monocytes Control Second-Phase Neutrophil Emigration in Established Lipopolysaccharide-induced Murine Lung Injury

Kevin Dhaliwal1, Emma Scholefield1, David Ferenbach1, Michael Gibbons1, Rodger Duffin1, David A. Dorward1, Andrew Conway Morris1, Duncan Humphries1, Alison MacKinnon1, Donald J. Davidson1, Nik Hirani1, Jeremy Hughes1, Chris Haslett1, and A. John Simpson1

1MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom; 2Institute of Life Science, Microbiology and Infection, School of Medicine, Swansea University, Swansea, Wales, United Kingdom; 3Department of Pathology, New Royal Infirmary, Edinburgh, United Kingdom; 4Department of Molecular Cell Biology, Vrije University, Amsterdam, The Netherlands; 5Department of Internal Medicine, University of Regensburg, Germany; and 6Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom

Keywords: acute lung injury; LPS; monocytes; neutrophils

Rationale: Acute lung injury (ALI) is an important cause of morbidity and mortality, with no currently effective pharmacological therapies. Neutrophils have been specifically implicated in the pathogenesis of ALI, and there has been significant research into the mechanisms of early neutrophil recruitment, but those controlling the later phases of neutrophil emigration that characterize disease are poorly understood.

Objectives: To determine the influence of peripheral blood monocytes (PBMs) in established ALI.

Methods: In a murine model of LPS-induced ALI, three separate models of conditional monocyte ablation were used: systemic liposomal clodronate (sLC), inducible depletion using CD11b diphtheria toxin receptor (CD11b DTR) transgenic mice, and antibody-dependent ablation of CCR2hi monocytes.

Measurements and Main Results: PBMs play a critical role in regulating neutrophil emigration in established murine LPS-induced lung injury. Gr1hi and Gr1lo PBM subpopulations contribute to this process. PBM depletion is associated with a significant reduction in measures of lung injury. The specificity of PBM depletion was demonstrated by replenishment studies in which the effects were reversed by systemic PBM infusion but not by systemic or local pulmonary infusion of mature macrophages or lymphocytes.

Conclusions: These results suggest that PBMs, or the mechanisms by which they influence pulmonary neutrophil emigration, could represent therapeutic targets in established ALI.

Keywords: acute lung injury; LPS; monocytes; neutrophils

The innate inflammatory response is geared to the clearance of pathogens, but excessive and persistent granulocyte accumulation is detrimental to the host (1). Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are characterized by neutrophil-mediated lung injury, the most common etiology being severe sepsis (2). Neutrophil-mediated lung injury of the epithelial/endothelial interface and consequent vascular leak are the hallmarks of ALI/ARDS (2–4). There are 200,000 cases per year of ALI in the United States, with a mortality of approximately 40% (2). No pharmacological agents have been shown convincingly to affect mortality. There is thus a pressing need to define critical mediators of neutrophil recruitment and to implement specific, mechanism-based therapeutic interventions.

The neutrophilic response in ALI has been described as occurring in two distinct phases (5): an initial “recruitment phase” mediated by chemokines followed by a “persistent phase” of neutrophil recruitment, possibly mediated in part by stromal-derived factor-1 (SDF-1/CXCL12) (5). Patients often present with established lung inflammation, and interventions must therefore be guided toward this second phase of neutrophil recruitment to reduce lung injury and ventilator dependence. The underlying cellular mechanisms driving this second phase of neutrophil recruitment remain to be fully characterized.

Peripheral blood monocytes (PBMs) are recruited alongside neutrophils in acute inflammation (6–10), and their potential importance in regulating and amplifying the inflammatory response is increasingly recognized (11, 12). Chemokine generation from recruited monocytes is implicated in effecting neutrophil recruitment (12, 13). These descriptions, alongside the recent discovery of patrolling sentinel monocytes within the vasculature (6), highlight PBMs’ potential role in sensing and directing the inflammatory response. The importance of PBMs in acute inflammation offers a potential therapeutic window because they mobilize from the bone marrow and circulate in the peripheral vasculature before tissue infiltration in...
investigating depletion in the MPS system (MPS) has been difficult. The majority of published models from its tissue descendents in the mononuclear phagocyte system (AM) in eliciting the inflammatory response in ALI have been reported. Delineating the role of the PBM independently of possible effects on the AM population. This highlights the role played by the resident alveolar macrophage (AM) in orchestrating early chemokine responses (20, 21).

To our knowledge, therapeutic depletion of PBMs timed to occur in the established phase of murine ALI has not previously been reported. Delineating the role of the PBM independently of its tissue descendents in the mononuclear phagocyte system (MPS) has been difficult. The majority of published models investigating depletion in the MPS system in vivo affect PBMs and tissue-resident macrophages (17–19). Indeed, studies have highlighted the role played by the resident alveolar macrophage (AM) in eliciting the inflammatory response in ALI through orchestration of early chemokine responses (20, 21).

In contrast to models used to study anatomical compartments such as the peritoneum and pleura (18, 19), it is possible to selectively ablate the PBM compartment without affecting resident AMs in murine models of lung inflammation (22). We used three independent techniques to deplete PBMs: systemic liposomal clodronate (sLC), diphtheria toxin (DT) administration in CD11b diphtheria toxin receptor (DTR) mice, and targeted antibody-dependent cell–mediated cytotoxicity (ADCC) depletion of monocytes (Table 1). Resident AM populations are unaffected by these three techniques. Compartmental AM depletion and lung macrophage replenishment studies confirmed that the attenuation of neutrophil recruitment was independent of possible effects on the AM population. This study therefore demonstrates the efficacy of temporal, targeted depletion of PBMs in established murine ALI. Some of the results of these studies have been previously reported in the form of an abstract (23).

### METHODS

#### Animals

Adult (25–35 g) specific pathogen-free BALB/c CD1/C57BL/6 mice and CD11b-DTR mice (FVB/N and C57BL/6 genetic background) were used. All studies were done under UK Home Office licenses 60/3545 and 60/3797.

#### LPS Lung Injury and BALF Retrieval

Unless otherwise indicated, 10 μg LPS from *Escherichia coli* (serotype O111:B4; Sigma-Aldrich, St. Louis, MO) in 50 μl PBS was given intratracheally. BALF was collected and weighed 48 hours later, and cell counts were adjusted per microliter of BALF retrieved. Cells were fixed and stained using a Quik-Diff kit (Reagenja, West Sussex, UK), and differential counts were determined.

#### Neutrophil Depletion

Neutrophil depletion (24) was achieved using monoclonal anti-mouse Ly-6G Ab (IA8 clone, rat IgG2a; BioXCell, West Lebanon, NH). Mice were given two injections of 1 mg Ly-6G Ab or isotype control in 100 μl of sterile saline intraperitoneally 6 and 24 hours after lung injury induction.

#### Monocyte Depletion

**Liposomal clodronate.** Liposomal clodronate (LC) was a gift of Roche Diagnostics GmbH (Mannheim, Germany). It was encapsulated in liposomes as previously described (25). LC or liposomal PBS (400 μl of each) were administered intraperitoneally 6 hours after intratracheal LPS, and a further 200 μl was administered 18 hours later. For AM depletion, 100 μl of LC or liposomal PBS were administered intratracheally 48 hours before intratracheal LPS.

**DT in CD11b-DTR.** DT (10 ng/g) (18, 19) was administered 6 and 24 hours after intratracheal LPS. For adoptive cell add-back experiments, age-, strain-, and sex-matched animals were used as controls, and DT was administered at the same intervals as described above.

**MC21 monoclonal antibody.** The CCR2-specific antibody MC21 (IgG2b) (20 μg) (26) was administered intraperitoneally 6 and 24 hours after intratracheal LPS. Control animals received isotype (IgG2b, clone 141945, MAB0061; R&D Systems, Minneapolis, MN).

#### Flow Cytometry Methods

Flow cytometry methods, including assessment of neutrophil transendothelial migration, are detailed in the online supplement.

#### Lung MPO Activity

Lung MPO activity was determined as previously described (27). Lung vascular permeability was determined as previously described (28) and is described further in the online supplement. Gravimetric determination of lung edema is described in the online supplement.

ELISA kits for measurement of IL-10, SDF-1, and KC in BAL fluids (DuoSet; R&D Systems) were used according to the manufacturer’s protocols.

**In Vivo optical Imaging**

*In vivo* optical imaging was performed on the Kodak MS FX Pro (Kodak Carestream, Rochester, NY) and the Visen FMT 2500 (Perkin-Elmer, Waltham, MA) as previously described (29). For vascular leak, 1.5 nmol of SAIVI albumin 680 (Invitrogen, Paisley, UK) was injected via the

### Table 1. Summary of Percentage Reduction of Alveolar Neutrophils after Monocyte Depletion in Lipopolysaccharide-Induced Acute Lung Injury

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Systemic Clodronate</th>
<th>DT in CD11b-DTR</th>
<th>MC21 mAb</th>
</tr>
</thead>
<tbody>
<tr>
<td>LPS (neutrophils/μl BAL)</td>
<td>3,561 ± 692.3</td>
<td>2,036 ± 413.9</td>
<td>2,488 ± 361.4</td>
</tr>
<tr>
<td>LPS plus treatment (neutrophils/μl BAL)</td>
<td>650.6 ± 135.9</td>
<td>408.6 ± 154.3</td>
<td>1,511 ± 177.0</td>
</tr>
<tr>
<td>p value</td>
<td>0.0036</td>
<td>0.0040</td>
<td>0.0182</td>
</tr>
<tr>
<td>% Reduction from control</td>
<td>70%</td>
<td>57%</td>
<td>76%</td>
</tr>
<tr>
<td>% Total neutrophile reduction in peripheral blood</td>
<td>82</td>
<td>80</td>
<td>39</td>
</tr>
<tr>
<td>% Gr-1&lt;sup&gt;+&lt;/sup&gt; reduction</td>
<td>70</td>
<td>95</td>
<td>35</td>
</tr>
<tr>
<td>% Gr-1&lt;sup&gt;-&lt;/sup&gt; reduction</td>
<td>74</td>
<td>95</td>
<td>74</td>
</tr>
<tr>
<td>% Gr-1&lt;sup&gt;-&lt;/sup&gt; reduction</td>
<td>53</td>
<td>90</td>
<td>4</td>
</tr>
</tbody>
</table>

*Definition of abbreviations: BAL = bronchoalveolar lavage; CD11b-DTR = CD11b diphtheria toxin receptor mice; DT = diphtheria toxin; Gr-1 = granulocyte-1; mAb = monoclonal antibody.*
lateral tail vein, and animals were imaged 30 minutes later. For lung protease activity, 1 nmol of a cathepsin-activatable probe (Prosense 750; Perkin-Elmer) or PBS control was instilled intratracheally 12 hours after intratracheal LPS. Images were acquired 24 hours after Prosense administration.

Cell Isolations
Bone marrow–derived macrophages (BMDMs) were harvested and generated from 8- to 12-week-old female mice as described previously (27). Viable cells (1 × 10^6) were instilled intratracheally 24 hours after intratracheal LPS. For intravenous reinfusions, 5 × 10^6 viable cells were administered by intravenous tail vein injection at 6 and 24 hours after intratracheal LPS. Mononuclear cell (MNC) isolation is detailed in the online supplement and is based on a published method (30). Cells (5 × 10^6) were infused intravenously 6 and 24 hours after intratracheal LPS. Lymphocyte controls were generated by negative magnetic selection using CD11b microbeads (Miltenyi Biotec, Surrey, UK). For optical imaging, cells were labeled with DiR (10 μM in PBS) (Invitrogen, Paisley, UK) (31).

Histology and F4/80 Immunohistochemistry
Histology and F4/80 immunohistochemistry were performed as previously described in subsets of animals without prior BAL (32). Histology scoring was conducted by a blinded observer (33).

Statistics
Student’s t test and Mann-Whitney U test were used for comparisons between two groups and one-way ANOVA with Bonferroni’s post hoc test for greater than two groups. For sequential samples, repeated measures two-way ANOVA with Bonferroni’s post hoc test was used. All analyses were conducted using GraphPad prism (V5.0, La Jolla, CA). In all data presented, *P < 0.05, **P < 0.01, ***P < 0.001.

RESULTS
Characterization of LPS-induced Lung Injury
A LPS-mediated model of lung injury was used (see Figure E1 in the online supplement) with intratracheal delivery of LPS. Maximum lung injury was observed at 48 hours, and the peak neutrophil count was observed at 24 hours. To demonstrate the continued influx of neutrophils between 12 and 48 hours after insult in this model, we used the neutrophil-specific depleting monoclonal antibody (mAb) Ly-6G (IA8 clone) (24). Systemic administration of the mAb 12 hours after LPS instillation yielded a 60% reduction in mean alveolar neutrophil count in bronchoalveolar lavage fluid (BALF) retrieved at 2 days (Figure E1). Forty-eight hours was chosen as the time point for BALF retrieval and tissue analysis in all further murine experimentation because it afforded time to apply therapeutic interventions after LPS administration and corresponded to maximal vascular leak and extravasated total protein in BALF.

Peripheral Administration of LC Depletes PBMs and Attenuates ALI
sLC has been shown to deplete 90% of PBMs within 24 hours in mice (25, 34) and tissue macrophages in the spleen and liver. In preliminary studies, biodistribution of fluorescently labeled sLC showed accumulation in the liver, spleen, and bone marrow with minimal accumulation in the lungs (Figure E2). Consistent with the biodistribution studies, F4/80-positive hepatic (112.7 ± 8.4

Figure 1. Characterization of the systemic administration of systemic liposomal clodronate (sLC). (A) sLC induces widespread resident F4/80 macrophage depletion in spleen and liver (original magnification: ×200) with no effect on resident alveolar macrophages (original magnification: ×40) compared with PBS liposomes (PBS L) (F4/80 staining indicated by brown color). (B) sLC does not affect blood neutrophil numbers in naive mice compared with PBS L (i.e., mice that have not been given LPS) (n = 7 per group). Data are presented as mean and 95% confidence interval. Not significant (P = 0.323) by Student’s t test.
vs. 4.66 ± 0.88 [mean ± SEM] cells per high-power field; $P = 0.0003$ by Student’s $t$ test) and splenic (35.69 ± 1.9 vs. 5.55 ± 0.22% percentage of area of F4/80 staining per high power field determined on Image J; $P < 0.0001$ by Student’s $t$ test) macrophages were ablated by sLC (Figure 1A) compared with animals receiving PBS liposomes. sLC did not reduce peripheral blood neutrophils (Figure 1B) or AM numbers retrieved from BALF (Figure E2). sLC did not lead to significant elevations in inflammatory cytokines in BALF (data not shown). The temporal depletion of PBMs using sLC is well characterized, with a nadir at 6 to 8 hours after LC administration with recrudescence of Gr-1$^+$ PBMs 18 hours later (34, 35). Hence, two sequential doses of intraperitoneal LC (6 and 24 h after LPS insult) were used to ensure sustained PBM depletion (Figure 2B). F4/80 staining of lungs in LPS-treated mice receiving PBS liposomes showed prominence of F4/80-positive infiltrating monocytes. In contrast, in sLC-treated animals, resident AMs were evident with reduced influx of F4/80-positive cells (Figure 2B). Histological assessment of lungs at 48 hours (Figure 2B) showed reduced neutrophil ingress and lung injury. Blinded scoring of histology showed a significant reduction in injury score (12.50 ± 0.76 vs. 6.0 ± 0.33; $P < 0.0001$ by Student’s $t$ test). PBM depletion after LPS administration significantly attenuated neutrophil numbers in BALF at 48 hours (Figure 2C). Additionally, total protein in BAL fluid (Figure 2D), lung edema (Figure 2E), and pulmonary vascular permeability were significantly reduced (Figure E2).

**LC Delivered Locally to the Lung Depletes AMs but Does Not Attenuate ALI**

In contrast to sLC, compartmental pulmonary LC delivery depletes AMs (32) (Figure E3) without having systemic effects. In keeping
with previous studies in rodents (36, 37), prior compartmental depletion of resident AMs did not reduce experimental pulmonary inflammation (Figure E3).

Characterization of the CD11b-DTR Mouse for PBM Depletion in ALI Models

To refine PBM depletion, we characterized ALI in the CD11b-DTR mouse, which expresses human DTR from CD11b promoter sequences, directing transgene expression to monocytes/macrophages after administration of very low concentrations of DT (18). A range of DT doses were tested in vivo, with 10 ng/g showing reduction of PBM by 90%. Despite the presence of CD11b on neutrophils, DT administration to CD11b-DTR mice did not affect the ability of granulocytes to up-regulate CD11b in response to LPS (Figure 3A) or neutrophil counts (Figures 3B–3D). BALF cells characterized morphologically as AMs retrieved from CD11b-DTR mice were phenotypically CD11b\text{lo} and CD11ch\text{i}, explaining their resistance to DT (Figure 3E). Similar to the effects of sLC treatment, DT administration to CD11b-DTR did not affect the numbers of AMs in BALF (Figure 3F). However, in contrast to sLC,
DT administration to CD11b-DTR mice did not ablate hepatic cells (95.4 ± 16.36 vs. 92.20 ± 11.89 cells per high-power field; \( P = 0.82 \) by Student’s \( t \) test) and had a much reduced depletion effect on splenic F4/80 staining (35.69 ± 1.9 vs. 17.47 ± 0.96 percentage of area of F4/80 staining per high-power field determined on Image J; \( P = 0.0011 \) by Student’s \( t \) test) (Figure 3G).

**DT Administration in CD11b-DTR Mice Attenuates ALI**

Having established that DT administration ablated blood monocytes (Figure 4A) (but not hepatic cells, AMs, or blood or bone marrow neutrophils) in vivo, we used the CD11b-DTR mouse to investigate the role of the PBM in ALI. PBM ablation using two consecutive doses of DT (10 ng/g) at 6 and 24 hours after LPS administration significantly attenuated neutrophil...

---

**Figure 4.** Peripheral blood monocyte (PBM) depletion in the CD11b-DTR mouse reduces ALI as evidenced by decreased neutrophil numbers, vascular leak, inflammatory cytokines, and improved oxygenation. (A) Diphtheria toxin (DT) in the CD11b-DTR mouse induces the depletion of granulocyte-1 (Gr-1\(^{hi}\)) and Gr-1\(^{lo}\) PBMs in the context of ongoing LPS-induced pulmonary inflammation. *Left panel* of each represents FSC/SSC plots and gating strategy for mononuclear cells. *Right panels* show CD11b versus Gr-1 staining of mononuclear cells in peripheral blood of mice showing an absence of CD11b\(^{hi}\) Gr-1\(^{hi}\) and Gr-1\(^{lo}\) monocytes in mice receiving DT versus PBS. Representative flow plots of \( n = 5 \) mice. Double-positive cells reduced from 9.24 to 1.73%. (B) In CD11b-DTR mice receiving intratracheal LPS, two doses of 10 ng/g DT led to reduced histological features of ALI and reduced infiltration of F4/80-positive (brown staining) PBMs with retained alveolar macrophages. (C) At 48 hours after LPS, there was a marked reduction in neutrophil numbers in bronchoalveolar lavage fluid (BALF) (\( n = 7 \) mice per group) in DT-treated CD11b-DTR mice compared with control mice. Data are presented as mean and 95% confidence interval (CI). \( P = 0.0003 \) by \( t \) test. (D) Accompanying the reduced neutrophil influx, there was reduced total protein in BALF in DT-treated CD11b-DTR mice compared with control mice, reflecting a reduction in epithelial-endothelial injury (\( n = 7 \) mice per group). Data are presented as mean and 95% CI. \( P = 0.029 \) by \( t \) test. (E) Stromal-derived factor-1 (SDF-1) was significantly decreased in BALF from CD11b-DTR mice receiving DT compared with control mice (\( n = 7 \) mice per group). Data are presented as mean and 95% CI. \( P = 0.0145 \) by \( t \) test. (F) IL-10 was significantly increased in BALF from CD11b-DTR mice receiving DT compared with control mice (\( n = 7 \) mice per group). Data are presented as mean and 95% CI. \( P = 0.013 \) by \( t \) test. (G) *Top panel:* Whole body reflectance imaging of mice after intravenous-labeled albumin showing reduced airway accumulation of albumin in the LPS-DT animal on the right in comparison to the PBS-DT animal on the left (representative animal from \( n = 3 \) per group that were imaged). *Bottom panel:* Cathepsin activity (measured 24 h after administration of Prosense 750) is also reduced in murine lungs after DT treatment (comparing LPS-DT mouse on the right with LPS-PBS mouse on the left). (H) In mice receiving 100 \( \mu \)g of LPS intratracheally followed by DT, at 48 hours there is significant improvement in oxygenation (\( n = 4 \) mice per group). Data are presented as mean and 95% CI. \( P = 0.028 \) by Mann Whitney test.
recruitment (Figures 4B and 4C). Histological assessment showed reduced lung injury and inflammatory infiltrates (Figure 4B). Blinded scoring of histology showed a significant reduction in injury score (12.30 ± 1.2 vs. 7.0 ± 0.17; P < 0.001 by Student’s t test). F4/80 staining of lungs showed reduced pulmonary ingress of monocytes with retained AMs (Figure 4B), and BALF analysis showed significantly reduced neutrophil numbers (Figure 4C) and total protein (as a measure of alveolar-endothelial disruption) (Figure 4D). There was no difference in the concentration of the key neutrophil chemokine KC in BALF at 48 hours by ELISA (data not shown). However, the recently characterized neutrophil chemokine SDF-1 was significantly reduced in mice that had received monocyte depletion by administration of DT (Figure 4E). Furthermore, lavage cytokines from these animals showed an antiinflammatory phenotype with increased IL-10 in monocyte-ablated animals (Figure 4F). Noninvasive whole-body optical imaging of treated mice also demonstrated a striking reduction in pulmonary vascular leak and protease activity (Figure 4G). Oxygenation of mice was assessed by performing arterial blood gas measurements in mice receiving 100 µg of LPS followed by monocyte depletion. This demonstrated significantly improved oxygenation (Figure 4H).

Pulmonary vascular permeability and lung function were also improved (Figure E2).

**DT Administration in CD11b-DTR Mice Attenuates Neutrophil Recruitment in a Model of Live Bacterial Infection**

To evaluate if neutrophil recruitment was dependent on monocytes in a model of direct bacterial instillation, we delivered 10⁶ colony-forming units of *Pseudomonas aeruginosa* followed by DT administration in the CD11b-DTR mouse. In this model, mice were lavaged 18 hours after bacterial instillation. There was a significant (P = 0.0002) reduction in alveolar neutrophil numbers but no significant difference in recoverable bacteria in BALF (Figure E4).

**Targeted Depletion of CCR2^{hi} (Gr-1^{hi}) PBMs Results in Attenuation of Neutrophil Numbers in BAL at 48 Hours**

sLC in wild-type mice and DT in the CD11b-DTR resulted in Gr-1^{hi} and Gr-1^{lo} PBM depletion. To test whether the effect was specific to particular PBM subtypes, we used low doses of an anti-CCR2 monoclonal antibody (MC21) to specifically deplete CCR2^{hi} Gr-1^{hi} PBMs (26). Preliminary studies confirmed that this dose of MC21 did not lead to peripheral blood neutrophil depletion in naive mice (n = 3 mice per group receiving 20 µg of MC21 or isotype control and neutrophil percentage in whole blood, was analyzed the following day; P = 0.7 using Mann-Whitney test). MC21 mAb (20 µg/mouse) was administered 6 hours after intratracheal LPS and then repeated 24 hours to maintain Gr-1^{hi} monocyte depletion (Figures 5A–5C). MC21 administration to LPS-treated mice resulted in a significant attenuation of neutrophil numbers in BALF (Figure 5D) and reduced myeloperoxidase (MPO, a neutrophil marker) in whole lung homogenates (Figure 5E) in comparison to isotype-treated control mice. In MC21-treated mice, there was a trend for a reduction in total BALF protein (Figure 5F). SDF-1 and pulmonary vascular permeability (Figure E2) were significantly reduced in MC21-treated mice.

**PBM Depletion Reduces Pulmonary Vascular Permeability and Improves Indices of Ventilation**

All of the PBM depletion methods significantly reduced pulmonary vascular leak measured by Evans blue (28) (Figure E2). Mice were subjected to whole-body plethysmography to record an index of ventilation. DT in the CD11b-DTR significantly improved an index of ventilation (Figure E2).

**PBM Depletion Reduces Pulmonary Interstitial Neutrophils**

Having demonstrated the reduced alveolar neutrophil influx after PBM depletion, we wished to determine if the pulmonary interstitial pool of neutrophils was reduced. Using methods recently described (38), we identified neutrophils in lung homogenates by dual staining for Ly6G and CD11b (Figure E6). Fluorescently labeled antibody against granulocyte-1 (Gr-1) was injected intravenously and served as a marker for intravascular neutrophils (CD11b^{hi}, Ly6G^{lo}, and Gr-1^{hi}). DT administration in CD11b-DTR mice and sLC in wild-type mice significantly reduced the total percentage of pulmonary interstitial neutrophils (Figure E6), suggesting a role for PBMs in transendothelial migration as recently described (39).

**Adaptive Intravenous Transfer of Mononuclear Cells but Not Macrophages Restores LPS-mediated Lung Inflammation**

To confirm that selective depletion of PBMs was responsible for the attenuation of neutrophil numbers in BAL, adoptive transfer experiments were performed. CD11b-DTR mice received intratracheal LPS at time 0 and intraperitoneal DT at 6 and 24 hours after LPS but also received adoptive transfer of various primary cells (obtained from syngeneic wild-type mice). Compartmental (pulmonary) and intravenous repletion studies were performed.

Compartmental pulmonary delivery of BMDMs to the LPS-treated lung after DT treatment had no effect on BAL neutrophil count at 48 hours (data not shown). Two infusions of intravenous primary murine BMDMs (5 × 10⁶) were then given to DT-treated mice with established LPS injury, which also failed to rescue neutrophil numbers in BALF (815 ± 201 neutrophils/µL BALF in wild-type mice receiving LPS and DT vs. 213 ± 46 neutrophils/µL BALF in DT-treated CD11b-DTR mice with LPS-induced ALI and macrophage infusion; P = 0.034 by Student’s t test; n = 5 per group). In contrast, intravenous adoptive transfusion of freshly isolated wild-type MNCs (5 × 10⁶) resulted in an increase of neutrophil numbers in BALF (Figure 6A) and a highly significant rescue of neutrophil numbers measured by flow cytometric Ly6G staining of single-cell suspensions of whole murine lungs (overall P < 0.0001) (Figure 6B). Lymphocytes isolated by negative magnetic selection from MNCs acted as cellular controls. Infusion of lymphocytes did not restore BALT or blood neutrophilia. Infused, labeled MNCs trafficked to the inflamed lung, to the liver, and to the spleen. In contrast, infused, labeled lymphocytes trafficked to liver and spleen but not to the inflamed lung (Figure E6).

Monocyte infiltration and dendritic cell (DC) maturation in the murine LPS–inflamed lung has been recently characterized, and MHC II^{hi} CD11c^{hi} CD11b^{lo} myeloid infiltrating DCs are potent producers of neutrophil chemokines (40). We therefore investigated expression of CD11b on monocyted subsets in lung tissue. There was a significant increase in CD11b expression on lung CD11c^{hi}, MHC II^{hi} cells in monocyte-depleted CD11b-DTR LPS-treated mice receiving MNC infusions (Figure 7), with partial rescue toward levels observed in LPS-treated wild-type mice, in marked contrast to those receiving lymphocytes.

**DISCUSSION**

Studies using rodent models of ALI demonstrate that the early influx of neutrophils is primarily directed by cytokine gradients...
generated from resident lung leukocytes and epithelial cells (41–43). This directs intraalveolar movement of neutrophils from the marginated pool within the lung and from the initial wave of bone marrow–mobilized neutrophils in the circulation (24). However, as we and others have shown, this initial wave of neutrophil-specific murine cytokines (KC, MIP-2) declines rapidly (18), and the factors controlling the sustained response remain unclear. Recent work implicates pulmonary epithelial cell–produced SDF-1 in later phase neutrophil recruitment (5), but the role of the innate immune cellular response in regulating the ongoing neutrophil influx is not clearly defined.

PBMs are increasingly being recognized in many organ systems as orchestrators of leukocyte recruitment (11, 22), prime initiators of endothelial damage (44, 45), and pivotal contributors to fibrogenesis (32, 46). However, despite the significant body of work suggesting that monocytes contribute to ALI (11, 13, 16, 39, 44, 45, 47–49), no published reports exist of therapeutic monocyte depletion in established experimental ALI. We hypothesized in this study that infiltrating PBMs play a major role in regulating ongoing neutrophil recruitment and consequent vascular leak and that depletion of the PBM pool is a therapeutic target in the setting of established ALI.

Given the controversy regarding the role of PBMs in ALI, we used three independent techniques in a LPS-induced ALI model, specifically aimed at investigating the function of PBMs in regulating the persistent phase of neutrophil recruitment in
ALI. In each case, treatments were administered for two consecutive days to ensure sustained depletion of PBMs (34, 35). Caveats for each individual depletion technique exist, but the observation that all three depletion strategies significantly attenuated neutrophil numbers in BALF (Table 1) in established ALI supports the general supposition.

The first technique we used was sLC administration. sLC has been extensively used in the literature to specifically deplete cells of the MPS (25). However, there have been few attempts to deplete PBMs in models of ALI using sLC (49, 50). These prior studies used early time points and showed no significant effects on neutrophil recruitment to the acutely inflamed lung but did not address later phase responses. A recent study using sLC depletion supported a role for monocytes in the transendothelial migration of neutrophils in an ischemia-reperfusion lung injury model (39), supporting our findings.

The treatment protocol we used resulted in a 70% reduction of PBMs (Gr-1hi and Gr-1lo subsets) without affecting resting neutrophils or resident AMs. However, there was also substantial ablation of hepatic and splenic macrophage pools and a consequent increase in the circulating number of neutrophils in the ALI model (data not shown). sLC resulted in a significant decrease in LPS-mediated neutrophil count in BALF at 48 hours. This divergent phenotype of decreased tissue neutrophils in the presence of significantly elevated blood neutrophilia closely resembles previous studies in an antiglomerular basement membrane model of renal injury (51). It is possible that the increased numbers of circulating neutrophils was due to their inadequate clearance by liver and splenic macrophages, which are depleted with sLC. Irrespectively, our observations suggested a major role for the PBM and/or its tissue descendents in the recruitment of neutrophils from the blood to the lung during the “persistent phase” of ALI.

We therefore used the transgenic CD11b-DTR mouse (18, 19), an inducible system with significantly less hepatic/splenic macrophage depletion (Figure 3G). In the setting of ALI, this transgenic system offers an effective means by which to specifically deplete Gr-1hi and Gr-1lo PBMs subsets. Unlike other tissue-resident macrophages, AMs are resistant to depletion owing to their low or absent expression of CCR2 (22), and neutrophils are not affected (18, 52, 53). Using this method for therapeutic PBM depletion in established murine ALI, there was a significant reduction in pulmonary neutrophil numbers in BALF at 48 hours. This corresponded with histological evidence of reduced lung injury (Figure 4B) and a significant reduction in SDF-1 in BALF. In the peripheral blood there was a significant reduction in neutrophilia, suggesting that the mobilization of neutrophils from bone marrow was reduced (data not shown). Given that the pulmonary production of SDF-1 is now recognized as a potential regulator of ongoing neutrophil recruitment to the inflamed lung, these findings suggest PBMs may contribute directly or indirectly to pulmonary SDF-1 expression.

sLC in wild-type mice and DT administration in CD11b-DTR mice led to depletion of the Gr-1hi and Gr-1lo monocyte subsets. Gr-1hi monocytes express CCR2 and have been described as the prime inflammatory monocyte subset (54). To determine if this subset contributed significantly to neutrophil influx, we used a low-dose antimurine CCR2 mAb that was unlikely to fully block the CCR2 axis (26) yet demonstrated direct ADCC of peripheral CCR2-expressing cells. This intervention resulted in...
a 95% reduction in Gr-1<sup>hi</sup> monocytes and led to a less striking reduction in pulmonary neutrophilia at 48 hours when compared with depletion of the Gr-1<sup>lo</sup> and Gr-1<sup>hi</sup> subsets. A caveat for this depletion methodology is that neutrophils do express CCR2. We showed in preliminary studies that low-dose MC21 did not deplete naïve murine neutrophils; however, this does not preclude depletion during inflammation because neutrophil CCR2 may be up-regulated, thereby increasing susceptibility to ADCC.

The question of whether AMs contributed to the reduction in neutrophil numbers in BALF was addressed by performing local compartmental ablation of resident AMs. This resulted in a trend for an increase in neutrophil numbers (not statistically significant) in BALF at 48 hours in mice receiving 10 μg of LPS in comparison to control ALI mice (Figure E3). This is similar to findings describing that depletion of AMs increases neutrophil recruitment (55). Indeed, these studies further support our contention that the AM is not directing the ongoing influx of neutrophils; rather, circulating monocytes are responsible.

Although systemic macrophage reconstitution had no phenotypic effect, MNC repletion partially rescued neutrophil numbers in whole lung after LPS treatment (Figure 6). In that regard, recent descriptions of monocyte emigration and maturation to pulmonary DCs and macrophages in naive and inflammatory situations (15, 56) highlight the possibility of targeting PBMs and impinging on DC/macrophage maturation in acute inflammation within the lung. Indeed, MNC rescue of neutrophil emigration in lungs (after DT administration in LPS-induced ALI in the CD11b-DTR mice) was associated with an inflammatory DC phenotype in lung digests (Figure 7) (CD11c<sup>hi</sup> MHC II<sup>hi</sup>, CD11b<sup>-</sup>). We did not perform lineage tracing studies to prove conclusively that myeloid-derived monocytes directly contributed to this population, but this supposition is supported by recent studies (40).

MNCs have been administered as a therapy in murine models of lung injury, but to up to now this strategy has been applied in the late stages of LPS-induced ALI. Indeed, Prota and colleagues (57) assessed therapeutic efficacy at 28 days after LPS administration and Yamada and colleagues at 1 week after LPS instillation (58). We speculate that the acute phase of inflammation driven by monocytes may be detrimental to the host and that late-phase mononuclear cell recruitment may be beneficial. In that regard, regulatory T lymphocytes (59) have been shown to be critical in the resolution of LPS-induced ALI through promoting neutrophil apoptosis. As such, the beneficial effects of MNC therapy in studies by Yamada and colleagues (58) and Prota and colleagues (57) may have been mediated via lymphocytes rather than monocytes.

We show data that PBMs facilitate pulmonary neutrophil recruitment in a model of live bacterial infection (Figure E4). However, this does not preclude potentially deleterious sequelae of PBM depletion in the setting of infection given the pleiotropic immunomodulatory functions of Gr1<sup>hi</sup> and Gr-1<sup>+</sup> monocyte subsets (13, 14, 32, 34, 35).

In summary, we have demonstrated that PBM depletion attenuates ALI, associated with consistent and significant reduction in neutrophil numbers in BALF and consequent tissue injury. However, determining the exact point at which to target this inflammatory response for optimal therapeutic benefit remains challenging. Nevertheless, by depleting monocytes and hence their tissue descendents in ALI, we have been able to sustain an injury-attenuation effect in the “persistent” phase of ALI. This supports the further study and development of monocyte-targeted therapies for ALI/ARDS.

References


Acknowledgment: The authors thank Fiona Rossi and Shona Johnston for assistance with flow cytometry.

Author disclosures are available with the text of this article at www.atlsjournals.org.


